Participants agreed not to drive while taking the study drug. The Parkinson trial therefore cannot be cited as a demonstration that its CBD/THC regimen preserved real-world driving ability.
The restriction shaped participation
The trial tested an oral CBD/THC solution against placebo in 61 randomized participants. Its eligibility and procedures included a no-driving agreement. The recruitment report identified driving restrictions, along with difficulties during the COVID period, among major reasons candidates did not proceed.
That requirement was part of the research setting. It was not an outcome showing that treated participants passed an on-road test.
Motor scores are not driving assessments
The primary endpoint was change in the motor portion of the Parkinson rating scale during usual medication treatment. Other clinical and cognitive assessments supplied additional information, but they did not become a validated measure of traffic performance simply because they involved motor or mental function.
Keep the external-validity question separate
People able to comply with a no-driving restriction may differ in practical circumstances from those who cannot. The report does not establish how that selection changed the treatment estimate. It does establish a limit on claims about everyday vehicle operation. Neither low measured plasma THC nor absence of a reported road incident in this restricted trial demonstrates driving safety.
Related reading: exposure evidence and driving impairment.
Research cited
Liu and colleagues (2024). Short-term cannabidiol with delta-9-tetrahydrocannabinol in Parkinson disease: a randomized trial. DOI: 10.1002/mds.29768.
Leave a Reply